Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) regularly issues news on its RNA interference (RNAi) pipeline, regulatory milestones, clinical data, and capital markets activity. This ARWR news page on Stock Titan aggregates those updates so readers can follow how the company’s gene-silencing therapeutics are progressing across cardiometabolic, obesity, and neurodegenerative indications.
Recent company announcements highlight approvals and regulatory actions for REDEMPLO (plozasiran), a small interfering RNA medicine targeting apoC-III for adults with familial chylomicronemia syndrome (FCS). Arrowhead has reported approvals for REDEMPLO in the United States, Canada, and China, as well as Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia and ongoing Phase 3 trials in broader triglyceride disorders.
News items also cover interim clinical data for investigational obesity candidates ARO-INHBE and ARO-ALK7, which the company is studying for effects on visceral fat, total fat, liver fat, and body weight, including in obese patients with type 2 diabetes mellitus. Additional coverage includes the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies such as Alzheimer’s disease, using a TRiM-based delivery system intended to reach the central nervous system after subcutaneous administration.
Investors and observers will also find Arrowhead’s press releases on public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032, as well as collaboration and licensing updates such as the agreement with Novartis for ARO-SNCA and arrangements involving Visirna Therapeutics and Sanofi in Greater China. Bookmark this page to review Arrowhead’s earnings-related 8-K references, conference participation, and ongoing disclosures about its RNAi programs and commercial activities.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported fiscal year 2020 results showing a significant revenue decline to $87.99 million from $168.80 million in 2019. The operating loss widened to $93.16 million, with a net loss of $84.55 million, translating to a diluted loss per share of $0.84. However, the company received a $20 million milestone from Amgen and achieved a strategic partnership with Takeda, including $300 million upfront and up to $740 million in milestones. Cash resources increased to $452.98 million, bolstering its financial position despite operating challenges.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced promising clinical data from its cardiometabolic pipeline at the AHA Scientific Sessions 2020. The company's investigational products, ARO-ANG3 and ARO-APOC3, showed strong responses in lipid parameters, addressing persistent cardiovascular risks. Notable presentations include pharmacodynamic effects targeting hypercholesterolemia and hypertriglyceridemia. Webinars on November 18 and 19 will further discuss these findings and future plans. These advancements position Arrowhead favorably in the competitive landscape of cardiovascular therapeutics.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announces positive interim results from its Phase 2 study AROAAT2002, evaluating ARO-AAT for treating alpha-1 antitrypsin deficiency (AATD). Patients receiving three doses showed significant reductions in the disease-causing Z-AAT protein, with serum reductions of 86-93% and liver reductions up to 95%. Improvements were noted in liver health biomarkers. The study indicates potential for accelerated regulatory discussions as further patient data is expected in the coming months.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in significant upcoming medical events. From November 13-16, 2020, at the Liver Meeting Digital Experience, they will present findings on ARO-AAT's effectiveness in reducing Z-AAT protein in patients with liver disease. At the AHA Scientific Sessions (November 13-17, 2020), the company will showcase multiple studies, including ARO-ANG3 and ARO-APOC3, targeting hypercholesterolemia and hypertriglyceridemia. CEO Chris Anzalone will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will host two webinars on November 18 and 19, 2020, focusing on its investigational RNA interference (RNAi) candidates ARO-APOC3 and ARO-ANG3. Key opinion leaders, Christie Ballantyne, M.D., and Ira Goldberg, M.D., will present on the unmet medical needs in treating hypertriglyceridemia and mixed dyslipidemia, respectively. Data from Phase 1/2 clinical studies for both candidates will also be presented at the American Heart Association's Scientific Sessions 2020. The webinars will be accessible through the company's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a conference call and webcast on November 23, 2020, at 4:30 p.m. EST to discuss its fiscal year 2020 financial results ending September 30. Investors can access the live event on the company’s website, with replay options available post-call. Arrowhead focuses on RNA interference-based therapeutics targeting serious diseases by silencing specific genes. The company aims to leverage its RNA chemistry portfolio to develop innovative treatments.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, at 1:30 p.m. EDT. Vince Anzalone, CFA, Arrowhead's VP and head of investor relations, will engage in a fireside chat presentation during this event. Presentation materials and webcast links will be available on the Events and Presentations section of their website. Arrowhead focuses on developing RNA interference-based therapies to combat intractable diseases.